Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection From Symptomatic Covid-19 Versus Placebo Over Six Months of Follow-up, With No Additional Doses, in Immunocompetent Participants
Invivyd第3期長期探索性臨床療效數據顯示，Pemgarda™（Pemivibart）在免疫能力正常的參與者中，在隨訪六個月內，相較安慰劑能夠顯著保護免受新冠病毒症狀，且無需額外劑量。
